IL282590A - Heavy chain antibodies that bind to CD38 - Google Patents
Heavy chain antibodies that bind to CD38Info
- Publication number
- IL282590A IL282590A IL282590A IL28259021A IL282590A IL 282590 A IL282590 A IL 282590A IL 282590 A IL282590 A IL 282590A IL 28259021 A IL28259021 A IL 28259021A IL 282590 A IL282590 A IL 282590A
- Authority
- IL
- Israel
- Prior art keywords
- heavy chain
- chain antibodies
- antibodies binding
- binding
- heavy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751520P | 2018-10-26 | 2018-10-26 | |
| PCT/US2019/058325 WO2020087065A1 (en) | 2018-10-26 | 2019-10-28 | Heavy chain antibodies binding to cd38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL282590A true IL282590A (en) | 2021-06-30 |
Family
ID=68610322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL282590A IL282590A (en) | 2018-10-26 | 2021-04-22 | Heavy chain antibodies that bind to CD38 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210388106A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3870611A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022505445A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210086651A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112955467A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019367218A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021000173A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3100232A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282590A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004732A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020087065A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299221A (en) | 2016-06-21 | 2023-02-01 | Teneobio Inc | Cd3 binding antibodies |
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| JP7240335B2 (ja) | 2017-06-20 | 2023-03-15 | テネオワン, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
| EA202091557A1 (ru) | 2017-12-22 | 2020-11-18 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 |
| CA3133654A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2022271987A1 (en) * | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| US20250277051A1 (en) * | 2021-08-02 | 2025-09-04 | Hangzhou Unogen Biotech, Ltd | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof |
| CN119403837A (zh) * | 2022-06-08 | 2025-02-07 | 上海华奥泰生物药业股份有限公司 | Cd39/cd73双特异性抗原结合蛋白及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| KR100944575B1 (ko) * | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| MXPA05004677A (es) | 2002-10-31 | 2005-11-17 | Genentech Inc | Metodos y composiciones para aumentar la produccion de anticuerpos. |
| WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| EP1776383B1 (en) | 2004-07-22 | 2014-08-20 | Erasmus University Medical Center Rotterdam | Binding molecules |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| AU2006312148B2 (en) | 2005-11-07 | 2012-04-12 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| US20100021473A1 (en) * | 2005-12-06 | 2010-01-28 | Domantis Limited | Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor |
| AU2007235413B2 (en) | 2006-04-05 | 2012-08-02 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| TWI507525B (zh) * | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| AU2012236210B2 (en) * | 2011-04-01 | 2016-02-04 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| AP2016009222A0 (en) * | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| PL3122781T3 (pl) * | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| CR20170526A (es) * | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| EP3374397A2 (en) * | 2015-11-10 | 2018-09-19 | University Medical Center Hamburg - Eppendorf | Antigen-binding polypeptides directed against cd38 |
| IL299221A (en) | 2016-06-21 | 2023-02-01 | Teneobio Inc | Cd3 binding antibodies |
| CN109862784A (zh) | 2016-08-24 | 2019-06-07 | 特尼奥生物股份有限公司 | 产生经修饰的仅有重链的抗体的转基因非人动物 |
| CR20220578A (es) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Anticuerpos de unión a cd3 |
| EP3559035A1 (en) * | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
-
2019
- 2019-10-28 WO PCT/US2019/058325 patent/WO2020087065A1/en not_active Ceased
- 2019-10-28 CA CA3100232A patent/CA3100232A1/en active Pending
- 2019-10-28 MX MX2021004732A patent/MX2021004732A/es unknown
- 2019-10-28 CN CN201980070019.4A patent/CN112955467A/zh active Pending
- 2019-10-28 BR BR112021000173-5A patent/BR112021000173A2/pt not_active IP Right Cessation
- 2019-10-28 US US17/288,485 patent/US20210388106A1/en not_active Abandoned
- 2019-10-28 AU AU2019367218A patent/AU2019367218A1/en not_active Abandoned
- 2019-10-28 JP JP2021521481A patent/JP2022505445A/ja active Pending
- 2019-10-28 KR KR1020217014808A patent/KR20210086651A/ko not_active Withdrawn
- 2019-10-28 EP EP19805819.0A patent/EP3870611A1/en not_active Withdrawn
-
2021
- 2021-04-22 IL IL282590A patent/IL282590A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021004732A (es) | 2021-06-04 |
| KR20210086651A (ko) | 2021-07-08 |
| CN112955467A (zh) | 2021-06-11 |
| CA3100232A1 (en) | 2020-04-30 |
| US20210388106A1 (en) | 2021-12-16 |
| WO2020087065A1 (en) | 2020-04-30 |
| JP2022505445A (ja) | 2022-01-14 |
| BR112021000173A2 (pt) | 2021-05-04 |
| AU2019367218A1 (en) | 2021-06-03 |
| EP3870611A1 (en) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287613A (en) | Antibodies that bind gprc5d | |
| IL279010B1 (en) | Heavy chain antibodies that bind to CD19 | |
| IL276537A (en) | Antibodies bind to GPRC5D | |
| IL286398A (en) | Heavy chain antibodies that bind to psma | |
| SG10202105788SA (en) | Antibodies binding to cd3 | |
| ZA202203250B (en) | Cd3 binding antibodies | |
| IL275498A (en) | Heavy chain antibodies that bind CD22 | |
| ZA201808209B (en) | Antibody for binding to interleukin 4 receptor | |
| ZA201801427B (en) | Antibodies that specifically bind to tl1a | |
| SG11202100096XA (en) | Antibodies binding to ilt4 | |
| IL273235A (en) | Heavy chain antibodies that bind to ectoenzymes | |
| IL269394A (en) | Antibodies bind to STEAP-1 | |
| HUE072731T2 (hu) | Egyszeres láncú variábilis fragmentumú CD3-kötõ proteinek | |
| ZA202104356B (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| SG11202106990PA (en) | BISPECIFIC ANTIBODY BINDING TO TfR | |
| PL3328886T3 (pl) | Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu | |
| HK40056602A (en) | Heavy chain antibodies binding to cd38 | |
| HK40078248A (en) | Heavy chain antibodies binding to cd38 | |
| HK40034161A (en) | Heavy chain antibodies binding to ectoenzymes | |
| HK40068892A (en) | Heavy chain antibodies binding to psma | |
| HK40039228A (en) | Heavy chain antibodies binding to cd22 | |
| GB201715149D0 (en) | IL-ß binding antibody |